New kidney drug HSK39297 moves to Long-Term safety trial
NCT ID NCT07616700
First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This study tests the long-term safety and effectiveness of HSK39297 tablets in 73 people with IgA nephropathy, a kidney disease. Participants who completed a previous study will take 200 mg daily, with a possible increase to 300 mg if urine protein remains high. The goal is to see if the drug can safely control the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
COMPLETEDBeijing, China
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSK39297 tablets
What this could lead to
If successful, this could provide a new oral treatment option to control IgA nephropathy and reduce protein in the urine, potentially slowing kidney damage.
What could go wrong
This is an early Phase 2 study with only 73 participants and no placebo group, so results may not confirm effectiveness. Long-term safety is still unknown, and dose increases depend on individual response.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.